Patient characteristics, immunologic responses, and clinical outcomes
UPN . | Age, y/sex . | Time from diagnosis, mo . | Current treatment . | HLA class I . | HLA class II . | CD4/CD8 responses* . | Baseline cytogenetics or molecular status . | Clinical outcome at end of vaccinations† . |
|---|---|---|---|---|---|---|---|---|
| 1 | 63/M | 11 | IFN-α | A2/3, B14/37 | DR01/13 | +/− | 45% Ph+ by karyopyte | No change |
| 2 | 44/M | 70 | IFN-α | A0201/2301, B18/41 | DR1104/1001 | +/− | 5% Ph+ by FISH | No change |
| 3 | 55/M | 8 | IFN-α | A0202/2902, B15/49 | DR1303/0701 | +/− | 100% Ph+ | Cytogenetic response to 25% Ph+ |
| 4 | 47/M | 3 | IFN-α | A1/65, B8 | DR17/52 | +/− | 95% Ph+ | Cytogenetic response to 15% Ph+ |
| 5 | 52/F | 60 | None | A0201/0301, B8/7 | DR0301/0104/04 | +/+ | PCR+ | Transient PCR− |
| 6 | 51/M | 138 | IFN-α | A0301/2402 B57/39 | DR0701/1602 | +/+ | 31% Ph+ | Cytogenetic response to 3% Ph+ |
| 7 | 25/F | 84 | None | A2.2/2.2, B13/61 | DR1406/07 | +/− | PCR+ | No change |
| 8 | 29/F | 102 | None | A1/2, B7/44 | DR15/7 | +/− | PCR+ | Cytogenetic relapse |
| 9 | 64/M | 1 | None | A11/32 B14/52 | DR01/13 | +/+ | 60% Ph+ | No change |
| 10 | 59/M | 11 | Hydroxyurea anagrelide, imatinib mesylate | A03/72, B15/35 | DR07/13 | +/+ | 100% Ph+ | Cytogenetic response, 14% Ph+ |
| 11 | 52/M | 10 | DLI | A0101/3001, B1503/1302 | DR1001/0701 | +/− | Cytogenetic relapse | Cytogenetic progression |
| 12 | 44/M | 13 | DLI | A0201/3001, B4402/1801 | DR1001/0301 | +/− | PCR+ | Transient PCR− |
| 13 | 50/M | 126 | DLI | A02/32, B35/47 | DR04/15 | +/− | PCR+ | Transient PCR− |
| 14 | 53/M | 9 | Imatinib mesylate | A02/2301, B1402/5801 | DR0102/1302 | +/− | PCR+ | No change |
UPN . | Age, y/sex . | Time from diagnosis, mo . | Current treatment . | HLA class I . | HLA class II . | CD4/CD8 responses* . | Baseline cytogenetics or molecular status . | Clinical outcome at end of vaccinations† . |
|---|---|---|---|---|---|---|---|---|
| 1 | 63/M | 11 | IFN-α | A2/3, B14/37 | DR01/13 | +/− | 45% Ph+ by karyopyte | No change |
| 2 | 44/M | 70 | IFN-α | A0201/2301, B18/41 | DR1104/1001 | +/− | 5% Ph+ by FISH | No change |
| 3 | 55/M | 8 | IFN-α | A0202/2902, B15/49 | DR1303/0701 | +/− | 100% Ph+ | Cytogenetic response to 25% Ph+ |
| 4 | 47/M | 3 | IFN-α | A1/65, B8 | DR17/52 | +/− | 95% Ph+ | Cytogenetic response to 15% Ph+ |
| 5 | 52/F | 60 | None | A0201/0301, B8/7 | DR0301/0104/04 | +/+ | PCR+ | Transient PCR− |
| 6 | 51/M | 138 | IFN-α | A0301/2402 B57/39 | DR0701/1602 | +/+ | 31% Ph+ | Cytogenetic response to 3% Ph+ |
| 7 | 25/F | 84 | None | A2.2/2.2, B13/61 | DR1406/07 | +/− | PCR+ | No change |
| 8 | 29/F | 102 | None | A1/2, B7/44 | DR15/7 | +/− | PCR+ | Cytogenetic relapse |
| 9 | 64/M | 1 | None | A11/32 B14/52 | DR01/13 | +/+ | 60% Ph+ | No change |
| 10 | 59/M | 11 | Hydroxyurea anagrelide, imatinib mesylate | A03/72, B15/35 | DR07/13 | +/+ | 100% Ph+ | Cytogenetic response, 14% Ph+ |
| 11 | 52/M | 10 | DLI | A0101/3001, B1503/1302 | DR1001/0701 | +/− | Cytogenetic relapse | Cytogenetic progression |
| 12 | 44/M | 13 | DLI | A0201/3001, B4402/1801 | DR1001/0301 | +/− | PCR+ | Transient PCR− |
| 13 | 50/M | 126 | DLI | A02/32, B35/47 | DR04/15 | +/− | PCR+ | Transient PCR− |
| 14 | 53/M | 9 | Imatinib mesylate | A02/2301, B1402/5801 | DR0102/1302 | +/− | PCR+ | No change |
UPN indicates unique patient number; M, male; IFN, interferon; Ph, Philadelphia chromosome; FISH, fluorescence in-situ hybridization; F, female; and DLI, donor lymphocyte infusion.
CD4 response measured by DTH, proliferation, interferon-gamma ELISPOT, and flow cytometry. CD8 response measured by interferon-gamma ELISPOT.
Patients 7, 10, 12, and 13 got 11 vaccinations; all others received 8 vaccinations.